Donepezil-d7

Donepezil-d7 (E2020-d7 (free base) ) is deuterium labeled Donepezil. Donepezil (E2020 free base) is a specific and potent AChE inhibitor with IC50s of 8.12 nM and 11.6 nM for bovine AChE and human AChE, respectively[1].

1215071-00-3

E2020-d7 (free base)

12352005

Cholinesterase (ChE) ; Isotope-Labeled Compounds

Neuronal Signaling; Others

Cancer-programmed cell death

Neurological Disease; Cancer

O=C1C(CC2CCN(C(C3=C([2H])C([2H])=C([2H])C([2H])=C3[2H])([2H])[2H])CC2)CC4=C1C=C(OC)C(OC)=C4

C24H22D7NO3

386.54

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Ogura, H., et al., Comparison of inhibitory activities of donepezil and other cholinesterase inhibitors on acetylcholinesterase and butyrylcholinesterase in vitro. Methods Find Exp Clin Pharmacol, 2000. 22 (8) : p. 609-13.|[3]Snape, M.F., et al., A comparative study in rats of the in vitro and in vivo pharmacology of the acetylcholinesterase inhibitors tacrine, donepezil and NXX-066. Neuropharmacology, 1999. 38 (1) : p. 181-93.|[4]Huang, Z.H., et al., Donepezil protects endothelial cells against hydrogen peroxide-induced cell injury. CNS Neurosci Ther, 2012. 18 (2) : p. 185-7.

Room temperature

http://file.medchemexpress.com/batch_PDF/HY-W727525/

Isotope-Labeled Compounds

No Development Reported